EverSource Wealth Advisors’s SAB Biotherapeutics SABS Stock Holding History

EverSource Wealth Advisors’s Portfolio SABS Stock Details SABS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$6	Buy	+2	New	+$7	﹤0.01%	4534

Other funds holding SABS

Vivo Capital Palo Alto, California $909M AUM 385.65% 1-Year Est. Return

BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM

Spruce Street Capital New York $629M AUM 210.46% 1-Year Est. Return

Sanofi Paris, France $630M AUM 104.49% 1-Year Est. Return

Affinity Asset Advisors New York $2.46B AUM 196.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Propel Bio Management Los Angeles, California $189M AUM 71.31% 1-Year Est. Return

Ensign Peak Advisors Salt Lake City, Utah $60.6B AUM 33.98% 1-Year Est. Return

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

EverSource Wealth Advisors's SABS Position: Q3 2026 in Review

EverSource Wealth Advisors opened a new position in SAB Biotherapeutics (SABS) in Q3 2026: 2 shares worth $6. The stake represents ﹤0.01% of the portfolio and ranks #4534 among its holdings.

61 funds tracked by Wall St. Rank hold SABS as of Q3 2026.

EverSource Wealth Advisors held 2 shares of SAB Biotherapeutics worth $6 as of Q3 2026.
SAB Biotherapeutics was a new EverSource Wealth Advisors position in Q3 2026.
SAB Biotherapeutics made up ﹤0.01% of EverSource Wealth Advisors's portfolio in Q3 2026, its #4534 holding.
61 funds tracked by Wall St. Rank held SAB Biotherapeutics as of Q3 2026.

Based on EverSource Wealth Advisors's 13F filing for Q3 2026, filed 4 Nov 2026.